Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Roivant Sciences Ltd. (ROIV : NSDQ)

• Company Description    Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK. Number of Employees: 750

• Price / Volume Information    Yesterday's Closing Price: $11.36 Daily Weekly Monthly 20 Day Moving Average: 7,426,752 shares Shares Outstanding: 679.81 (millions) Market Capitalization: $7,722.60 (millions) Beta: 1.15 52 Week High: $13.06 52 Week Low: $8.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.35% -4.18% 12 Week 11.92% -5.55% Year To Date -3.97% -9.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7th Floor 50 Broadway - LONDON,X0 SW1H 0DB GBR ph: 44-20-7400-3347 fax: - keyur.parekh@roivant.com https://roivant.com

• General Corporate Information    Officers Matthew Gline - Chief Executive Officer and Director Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Jennifer Humes - Chief Accounting Officer Keith Manchester - Director Peer Information Roivant Sciences Ltd. (CORR.) Roivant Sciences Ltd. (RSPI) Roivant Sciences Ltd. (CGXP) Roivant Sciences Ltd. (BGEN) Roivant Sciences Ltd. (GTBP) Roivant Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G76279101 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 679.81 Most Recent Split Date: (:1) Beta: 1.15 Market Capitalization: $7,722.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.52 Price/Cash Flow: - Price / Sales: 101.35 EPS Growth vs. Year Ago Period: -10.71% vs. Previous Quarter: -55.00% Sales Growth vs. Year Ago Period: -73.83% vs. Previous Quarter: -16.06% ROE 06/30/25 - - 03/31/25 - -14.76 12/31/24 - -14.05 ROA 06/30/25 - - 03/31/25 - -13.69 12/31/24 - -12.81 Current Ratio 06/30/25 - - 03/31/25 - 33.47 12/31/24 - 37.91 Quick Ratio 06/30/25 - - 03/31/25 - 33.47 12/31/24 - 37.91 Operating Margin 06/30/25 - - 03/31/25 - -1,075.13 12/31/24 - -844.54 Net Margin 06/30/25 - - 03/31/25 - -225.71 12/31/24 - -119.54 Pre-Tax Margin 06/30/25 - - 03/31/25 - -2,346.02 12/31/24 - -417.14 Book Value 06/30/25 - - 03/31/25 - 7.45 12/31/24 - 7.69 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©